Literature DB >> 22483327

Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score.

Philippe Généreux1, Tullio Palmerini, Adriano Caixeta, Gregg Rosner, Philip Green, Ovidiu Dressler, Ke Xu, Helen Parise, Roxana Mehran, Patrick W Serruys, Gregg W Stone.   

Abstract

OBJECTIVES: The purpose of this study was to quantify the extent and complexity of residual coronary stenoses following percutaneous coronary intervention (PCI) and to evaluate its impact on adverse ischemic outcomes.
BACKGROUND: Incomplete revascularization (IR) after PCI is common, and most studies have suggested that IR is associated with a worse prognosis compared with complete revascularization (CR). However, formal quantification of the extent and complexity of residual atherosclerosis after PCI has not been performed.
METHODS: The baseline Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) score (bSS) from 2,686 angiograms from patients with moderate- and high-risk acute coronary syndrome (ACS) undergoing PCI enrolled in the prospective ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial was determined. The SS after PCI was also assessed, generating the "residual" SS (rSS). Patients with rSS >0 were defined as having IR and were stratified by rSS tertiles, and their outcomes were compared to the CR group.
RESULTS: The bSS was 12.8 ± 6.7, and after PCI the rSS was 5.6 ± 2.2. Following PCI, 1,084 patients (40.4%) had rSS = 0 (CR), 523 (19.5%) had rSS >0 but ≤2, 578 (21.5%) had rSS >2 but ≤8, and 501 patients (18.7%) had rSS >8. Age, insulin-treated diabetes, hypertension, smoking, elevated biomarkers or ST-segment deviation, and lower ejection fraction were more frequent in patients with IR compared with CR. The 30-day and 1-year rates of ischemic events were significantly higher in the IR group compared with the CR group, especially those with high rSS. By multivariable analysis, rSS was a strong independent predictor of all ischemic outcomes at 1 year, including all-cause mortality (hazard ratio: 1.05, 95% confidence interval: 1.02 to 1.09, p = 0.006).
CONCLUSIONS: The rSS is useful to quantify and risk-stratify the degree and complexity of residual stenosis after PCI. Specifically, rSS >8.0 after PCI in patients with moderate- and high-risk ACS is associated with a poor 30-day and 1-year prognosis. (Comparison of Angiomax Versus Heparin in Acute Coronary Syndromes; NCT00093158).
Copyright © 2012 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22483327      PMCID: PMC3725642          DOI: 10.1016/j.jacc.2012.03.010

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  34 in total

1.  The effect of completeness of revascularization on event-free survival at one year in the ARTS trial.

Authors:  Marcel J B M van den Brand; Benno J W M Rensing; Marie-angèle M Morel; David P Foley; Vincent de Valk; Arno Breeman; Harry Suryapranata; Maximiliaan M P Haalebos; William Wijns; Francis Wellens; Rafael Balcon; Patrick Magee; Expedito Ribeiro; Enio Buffolo; Felix Unger; Patrick W Serruys
Journal:  J Am Coll Cardiol       Date:  2002-02-20       Impact factor: 24.094

2.  SYNTAX score and Clinical SYNTAX score as predictors of very long-term clinical outcomes in patients undergoing percutaneous coronary interventions: a substudy of SIRolimus-eluting stent compared with pacliTAXel-eluting stent for coronary revascularization (SIRTAX) trial.

Authors:  Chrysafios Girasis; Scot Garg; Lorenz Räber; Giovanna Sarno; Marie-Angèle Morel; Hector M Garcia-Garcia; Thomas F Lüscher; Patrick W Serruys; Stephan Windecker
Journal:  Eur Heart J       Date:  2011-09-27       Impact factor: 29.983

3.  Usefulness of the SYNTAX score for predicting clinical outcome after percutaneous coronary intervention of unprotected left main coronary artery disease.

Authors:  Davide Capodanno; Maria Elena Di Salvo; Glauco Cincotta; Marco Miano; Claudia Tamburino; Corrado Tamburino
Journal:  Circ Cardiovasc Interv       Date:  2009-06-30       Impact factor: 6.546

4.  A patient-level pooled analysis assessing the impact of the SYNTAX (synergy between percutaneous coronary intervention with taxus and cardiac surgery) score on 1-year clinical outcomes in 6,508 patients enrolled in contemporary coronary stent trials.

Authors:  Scot Garg; Giovanna Sarno; Chrysafios Girasis; Pascal Vranckx; Ton de Vries; Michael Swart; Marco Bressers; Hector M Garcia-Garcia; Gerrit-Anne van Es; Lorenz Räber; Gianluca Campo; Marco Valgimigli; Keith D Dawkins; Stephan Windecker; Patrick W Serruys
Journal:  JACC Cardiovasc Interv       Date:  2011-06       Impact factor: 11.195

5.  Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation.

Authors:  Pim A L Tonino; William F Fearon; Bernard De Bruyne; Keith G Oldroyd; Massoud A Leesar; Peter N Ver Lee; Philip A Maccarthy; Marcel Van't Veer; Nico H J Pijls
Journal:  J Am Coll Cardiol       Date:  2010-06-22       Impact factor: 24.094

6.  Long-term outcome of angioplasty for multivessel coronary disease: importance and price of complete revascularization.

Authors:  U C Kloeter; N G Jander; P T Buser; S Osswald; J Mueller-Brand; M E Pfisterer
Journal:  Int J Cardiol       Date:  2001-07       Impact factor: 4.164

7.  Functional SYNTAX score for risk assessment in multivessel coronary artery disease.

Authors:  Chang-Wook Nam; Fabio Mangiacapra; Robert Entjes; In-Sung Chung; Jan-Willem Sels; Pim A L Tonino; Bernard De Bruyne; Nico H J Pijls; William F Fearon
Journal:  J Am Coll Cardiol       Date:  2011-09-13       Impact factor: 24.094

8.  Bivalirudin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a subgroup analysis from the Acute Catheterization and Urgent Intervention Triage strategy (ACUITY) trial.

Authors:  Gregg W Stone; Harvey D White; E Magnus Ohman; Michel E Bertrand; A Michael Lincoff; Brent T McLaurin; David A Cox; Stuart J Pocock; James H Ware; Frederick Feit; Antonio Colombo; Steven V Manoukian; Alexandra J Lansky; Roxana Mehran; Jeffrey W Moses
Journal:  Lancet       Date:  2007-03-17       Impact factor: 79.321

9.  Incomplete revascularization in the era of drug-eluting stents: impact on adverse outcomes.

Authors:  Edward L Hannan; Chuntao Wu; Gary Walford; David R Holmes; Robert H Jones; Samin Sharma; Spencer B King
Journal:  JACC Cardiovasc Interv       Date:  2009-01       Impact factor: 11.195

10.  Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.

Authors:  Leslee J Shaw; Daniel S Berman; David J Maron; G B John Mancini; Sean W Hayes; Pamela M Hartigan; William S Weintraub; Robert A O'Rourke; Marcin Dada; John A Spertus; Bernard R Chaitman; John Friedman; Piotr Slomka; Gary V Heller; Guido Germano; Gilbert Gosselin; Peter Berger; William J Kostuk; Ronald G Schwartz; Merill Knudtson; Emir Veledar; Eric R Bates; Benjamin McCallister; Koon K Teo; William E Boden
Journal:  Circulation       Date:  2008-02-11       Impact factor: 29.690

View more
  53 in total

1.  Complete versus incomplete coronary revascularization of patients with multivessel coronary artery disease.

Authors:  Yader Sandoval; Emmanouil S Brilakis; Mariana Canoniero; Demetris Yannopoulos; Santiago Garcia
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-03

Review 2.  Anticoagulant Therapy for Acute Coronary Syndromes.

Authors:  Eunice Nc Onwordi; Amr Gamal; Azfar Zaman
Journal:  Interv Cardiol       Date:  2018-05

Review 3.  Complete versus incomplete coronary revascularization: definitions, assessment and outcomes.

Authors:  Prakriti Gaba; Bernard J Gersh; Ziad A Ali; Jeffrey W Moses; Gregg W Stone
Journal:  Nat Rev Cardiol       Date:  2020-10-16       Impact factor: 32.419

4.  The relationship between revascularization extent and the long-term prognosis of patients with stable angina pectoris and three-vessel disease treated by percutaneous coronary intervention in the era of drug-eluting stents.

Authors:  Quan Li; Xianpeng Yu; Jiqiang He; Yuechun Gao; Xiaoling Zhang; Changyan Wu; Yawei Luo; Yuchen Zhang; Xuejun Ren; Shuzheng Lv; Fang Chen
Journal:  Clin Cardiol       Date:  2014-08-14       Impact factor: 2.882

5.  Relationship Between Age and Trajectories of Rehospitalization Risk in Older Adults.

Authors:  Kumar Dharmarajan; Angela Hsieh; Rachel P Dreyer; Jack Welsh; Li Qin; Harlan M Krumholz
Journal:  J Am Geriatr Soc       Date:  2016-11-22       Impact factor: 5.562

6.  Is Complete Revascularisation Mandated for all Patients with Multivessel Coronary Artery Disease?

Authors:  Carlo De Innocentiis; Marco Zimarino; Raffaele De Caterina
Journal:  Interv Cardiol       Date:  2018-01

7.  How and when to decide on revascularization in stable ischemic heart disease.

Authors:  Alicia Mecklai; Sripal Bangalore; Judith Hochman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-02

8.  Complete revascularization determined by myocardial perfusion imaging could improve the outcomes of patients with stable coronary artery disease, compared with incomplete revascularization and no revascularization.

Authors:  Jiehui Li; Xiubin Yang; Yueqin Tian; Hongxing Wei; Marcus Hacker; Xiang Li; Xiaoli Zhang
Journal:  J Nucl Cardiol       Date:  2017-12-06       Impact factor: 5.952

9.  Percutaneous Treatment of Coronary Chronic Total Occlusions Part 1: Rationale and Outcomes.

Authors:  Alfredo Galassi; Aaron Grantham; David Kandzari; William Lombardi; Issam Moussa; Craig Thompson; Gerald Werner; Charles Chambers; Emmanouil Brilakis
Journal:  Interv Cardiol       Date:  2014-08

Review 10.  Risk Stratification in Patients with Coronary Artery Disease: A Practical Walkthrough in the Landscape of Prognostic Risk Models.

Authors:  Sergio Buccheri; Paolo D'Arrigo; Gabriele Franchina; Davide Capodanno
Journal:  Interv Cardiol       Date:  2018-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.